UNCYUnicycive Therapeutics, Inc.

Nasdaq unicycive.com


$ 1.07 $ 0.02 (1.92 %)    

Monday, 20-May-2024 15:57:16 EDT
QQQ $ 454.82 $ 3.15 (0.7 %)
DIA $ 398.57 $ -1.85 (-0.46 %)
SPY $ 530.36 $ 0.61 (0.12 %)
TLT $ 91.26 $ -0.27 (-0.3 %)
GLD $ 225.37 $ 0.90 (0.4 %)
$ 1.06
$ 1.06
$ 0.00 x 0
$ 0.00 x 0
$ 1.06 - $ 1.07
$ 0.47 - $ 1.82
103,990
na
39.86M
$ -2.22
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-16-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-31-2022 12-31-2021 10-K
11 11-11-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-unicycive-therapeutics-maintains-45-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $4.5 price ...

 unicycive-therapeutics-q1-2024-gaap-eps-061-misses-015-estimate

Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate...

 benchmark-reiterates-speculative-buy-on-unicycive-therapeutics-maintains-3-price-target

Benchmark analyst Bruce Jackson reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and maintains $3 pric...

 piper-sandler-initiates-coverage-on-unicycive-therapeutics-with-overweight-rating-announces-price-target-of-9

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Unicycive Therapeutics (NASDAQ:UNCY) with a Overweight rating and...

 correction-on-friday-unicycive-therapeutics-reported-q4-eps-of-022-which-missed-017-estimate

Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate...

 hc-wainwright--co-reiterates-buy-on-unicycive-therapeutics-maintains-45-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $4.5 price ...

 why-limbach-holdings-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarte...

 hc-wainwright--co-reiterates-buy-on-unicycive-therapeutics-maintains-45-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $4.5 price ...

 hc-wainwright--co-reiterates-buy-on-unicycive-therapeutics-maintains-45-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $4.5 price ...

 hc-wainwright--co-reiterates-buy-on-unicycive-therapeutics-maintains-45-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $4.5 price ...

 unicycive-therapeutics-announces-orphan-drug-designation-granted-for-uni-494-by-the-us-food-and-drug-administration-for-the-prevention-of-delayed-graft-function-in-kidney-transplant-patients

Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidne...

 noble-capital-markets-initiates-coverage-on-unicycive-therapeutics-with-outperform-rating-announces-price-target-of-6

Noble Capital Markets analyst Robert LeBoyer initiates coverage on Unicycive Therapeutics (NASDAQ:UNCY) with a Outperform ra...

 why-3m-shares-are-trading-lower-by-over-12-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of 3M Company (NYSE: MMM) fell sharply during Tuesday’s session after the company reported better-than-expected fourth-q...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION